Prevention and treatment of acute renal failure in sepsis

Journal of the American Society of Nephrology

Volumn 14, Issue 3, 2003, Pages 792-805

  De Vriese, An S ^a  

^a General Hospital St Jan   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANARITIDE; ARGIPRESSIN; ATRIAL NATRIURETIC FACTOR; BAY 1351; BLOOD CLOTTING INHIBITOR; CONTRAST MEDIUM; DIURETIC AGENT; DOPAMINE; ENDOTHELIN RECEPTOR ANTAGONIST; FUROSEMIDE; HYPERTENSIVE FACTOR; IBUPROFEN; INDOMETACIN; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; LEUKOCYTE ELASTASE INHIBITOR; LOOP DIURETIC AGENT; METHYLISOTHIOUREA; N(G) METHYLARGININE; N(G) NITROARGININE METHYL ESTER; N6 (1 IMINOETHYL)LYSINE; NITRIC OXIDE SYNTHASE INHIBITOR; NORADRENALIN; PROSTAGLANDIN SYNTHASE INHIBITOR; THIOUREA DERIVATIVE; THROMBOCYTE ACTIVATING FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; URODILATIN; VASOPRESSIN;

ACUTE KIDNEY FAILURE; ADENOHYPOPHYSIS HORMONE SUPPRESSION; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COLLOID; CRYSTALLOID; DRUG EFFECT; DRUG FATALITY; DRUG INDICATION; FLUID THERAPY; HEART MUSCLE ISCHEMIA; HORMONE INHIBITION; HUMAN; HYPOTENSION; INFLAMMATORY CELL; KIDNEY DISEASE; KIDNEY PERFUSION; NONHUMAN; PRIORITY JOURNAL; RESPIRATION DEPRESSION; RESUSCITATION; SEPSIS; SIDE EFFECT; T LYMPHOCYTE; T LYMPHOCYTE DEPRESSION; TACHYCARDIA; TREATMENT INDICATION;

EID: 0037371583     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000055652.37763.F7     Document Type: Article

References (138)

1. Neveu H, Kleinknecht D, Brivet F, Loirat P, Landais P: Prognostic factors in acute renal failure due to sepsis. Results of a prospective multicentre study. The French Study Group on Acute Renal Failure. Nephrol Dial Transplant 11: 293-299, 1996
2. Levy EM, Viscoli CM, Horwitz RI: The effect of acute renal failure on mortality. A cohort analysis. JAMA 275: 1489-1494, 1996
3. a. Cohen J: The immunopathogenesis of sepsis. Nature 420: 885-887, 2002
4. b. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 348: 138-150, 2003
5. Khan RZ, Badr KF: Endotoxin and renal function: perspectives to the understanding of septic acute renal failure and toxic shock. Nephrol Dial Transplant 14: 814-818, 1999
6. Gattinoni L, Brazzi L, Pelosi P, Latini R, Tognoni G, Pesenti A, Fumagalli R: A trial of goal-oriented hemodynamic therapy in critically ill patients. SvO2 Collaborative Group. N Engl J Med 333: 1025-1032, 1995
7. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345: 1368-1377, 2001
8. Cochrane Injuries Group Albumin Reviewers: Human albumin administration in critically ill patients: Systematic review of randomised controlled trials. BMJ 317: 235-240, 1998
9. Schierhout G, Roberts I: Fluid resuscitation with colloid or crystalloid solutions in critically ill patients: A systematic review of randomised trials. BMJ 1998 316: 961-964, 1998
10. Choi PT, Yip G, Quinonez LG, Cook DJ: Crystalloids vs. colloids in fluid resuscitation: A systematic review. Crit Care Med 27: 200-210, 1999
11. Schortgen F, Lacherade JC, Bruneel F, Cattaneo I, Hemery F, Lemaire F, Brochard L: Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: A multicentre randomised study. Lancet 357: 911-916, 2001
12. Cittanova ML, Leblanc I, Legendre C, Mouquet C, Riou B, Coriat P: Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients. Lancet 348: 1620-1622, 1996
13. Boldt J, Muller M, Mentges D, Papsdorf M, Hempelmann G: Volume therapy in the critically ill: Is there a difference? Intensive Care Med 24: 28-36, 1998
14. Schetz M: Vasopressors and the kidney. Blood Purif 20: 243-251, 2002
15. Martin C, Papazian L, Perrin G, Saux P, Gouin F: Norepinephrine or dopamine for the treatment of hyperdynamic septic shock? Chest 103: 1826-1831, 1993
16. Martin C, Viviand X, Leone M, Thirion X: Effect of norepinephrine on the outcome of septic shock. Crit Care Med 28: 2758-2765, 2000
17. rd: Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med 29: 487-493, 2001
18. Patel BM, Chittock DR, Russell JA, Walley KR: Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 96: 576-582, 2002
19. Krismer AC, Wenzel V, Mayr VD, Voelckel WG, Strohmenger HU, Lurie K, Lindner KH: Arginine vasopressin during cardiopulmonary resuscitation and vasodilatory shock: Current experience and future perspectives. Curr Opin Crit Care 7: 157-169, 2001
20. Denton MD, Chertow GM, Brady HR: "Renal-dose" dopamine for the treatment of acute renal failure: Scientific rationale, experimental studies and clinical trials. Kidney Int 50: 4-14, 1996
21. Burton CJ, Tomson CR: Can the use of low-dose dopamine for treatment of acute renal failure be justified? Postgrad Med J 75: 269-274, 1999
22. Duke GJ, Briedis JH, Weaver RA: Renal support in critically ill patients: Low-dose dopamine or low-dose dobutamine? Crit Care Med 22: 1919-1925, 1994
23. Chertow GM, Sayegh MH, Allgren RL, Lazarus JM: Is the administration of dopamine associated with adverse or favorable outcomes in acute renal failure? Auriculin Anaritide Acute Renal Failure Study Group. Am J Med 101: 49-53, 1996
24. Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J: Low-dose dopamine in patients with early renal dysfunction: A placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 356: 2139-2143, 2000
25. Segal JM, Phang PT, Walley KR: Low-dose dopamine hastens onset of gut ischemia in a porcine model of hemorrhagic shock. J Appl Physiol 73: 1159-1164, 1992
26. Van den Berghe G, de Zegher F: Anterior pituitary function during critical illness and dopamine treatment. Crit Care Med 24: 1580-1590, 1996
27. Solomon R, Werner C, Mann D, D'Elia J, Silva P: Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 331: 1416-1420, 1994
28. Lassnigg A, Donner E, Grubhofer G, Presterl E, Druml W, Hiesmayr M: Lack of renoprotective effects of dopamine and furosemide during cardiac surgery. J Am Soc Nephrol 11: 97-104, 2000
29. Cantarovich F, Fernandez JC, Locatelli A, Perez Loredo J, Christhot J: Frusemide in high doses in the treatment of acute renal failure. Postgrad Med J 47[Suppl]: 13-17, 1971
30. Cantarovich F, Galli C, Benedetti L, Chena C, Castro L, Correa C, Perez Loredo J, Fernandez JC, Locatelli A, Tizado J: High dose frusemide in established acute renal failure. Br Med J 4: 449-450, 1973
31. Minuth AN, Terrell JB Jr, Suki WN: Acute renal failure: A study of the course and prognosis of 104 patients and of the role of furosemide. Am J Med Sci 271: 317-324, 1976
32. Kleinknecht D, Ganeval D, Gonzalez-Duque LA, Fermanian J: Furosemide in acute oliguric renal failure. A controlled trial. Nephron 17: 51-58, 1976
33. Borirakchanyavat V, Vongsthongsri M, Sitprija V: Furosemide and acute renal failure. Postgrad Med J 54: 30-32, 1978
34. Brown CB, Ogg CS, Cameron JS: High dose frusemide in acute renal failure: A controlled trial. Clin Nephrol 15: 90-96, 1981
35. Shilliday IR, Quinn KJ, Allison ME: Loop diuretics in the management of acute renal failure: A prospective, double-blind, placebo-controlled, randomized study. Nephrol Dial Transplant 12: 2592-2596, 1997
36. Anderson RJ, Linas SL, Berns AS, Henrich WL, Miller TR, Gabow PA, Schrier RW: Nonoliguric acute renal failure. N Engl J Med 296: 1134-1138, 1977
37. Mehta RL, Pascual MT, Soroko S, Chertow GM; PICARD Study Group: Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA 288: 2547-2553, 2002
38. Martin SJ, Danziger LH: Continuous infusion of loop diuretics in the critically ill: A review of the literature. Crit Care Med 22: 1323-1329, 1994
39. Baud L, Oudinet JP, Bens M, Noe L, Peraldi MN, Rondeau E, Etienne J, Ardaillou R: Production of tumor necrosis factor by rat mesangial cells in response to bacterial lipopolysaccharide. Kidney Int 35: 1111-1118, 1989
40. Bertani T, Abbate M, Zoja C, Corna D, Perico N, Ghezzi P, Remuzzi G: Tumor necrosis factor induces glomerular damage in the rabbit. Am J Pathol 134: 419-430, 1989
41. van der Veen AH, Seynhaeve AL, Breurs J, Nooijen PT, Marquet RL, Eggermont AM: In vivo isolated kidney perfusion with tumour necrosis factor alpha (TNF-alpha) in tumour-bearing rats. Br J Cancer 79: 433-439, 1999
42. Messmer UK, Briner VA, Pfeilschifter J: Tumor necrosis factor-alpha and lipopolysaccharide induce apoptotic cell death in bovine glomerular endothelial cells. Kidney Int 55: 2322-2337, 1999
43. Reinhart K, Karzai W: Anti-tumor necrosis factor therapy in sepsis: Update on clinical trials and lessons learned. Crit Care Med 29(7 Suppl): S121-S125, 2001
44. Fiedler VB, Loof I, Sander E, Voehringer V, Galanos C, Fournel MA: Monoclonal antibody to tumor necrosis factor-alpha prevents lethal endotoxin sepsis in adult rhesus monkeys. J Lab Clin Med 120: 574-588, 1992
45. Knotek M, Rogachev B, Wang W, Ecder T, Melnikov V, Gengaro PE, Esson M, Edelstein CL, Dinarello CA, Schrier RW: Endotoxemic renal failure in mice: Role of tumor necrosis factor independent of inducible nitric oxide synthase. Kidney Int 59: 2243-2249, 2001
46. Cunningham PN, Dyanov HM, Park P, Wang J, Newell KA, Quigg RJ: Acute renal failure in endotoxemia is caused by TNF acting directly on TNF receptor-1 in kidney. J Immunol 168: 5817-5823, 2002
47. Peschon JJ, Torrance DS, Stocking KL, Glaccum MB, Otten C, Willis CR, Charrier K, Morrissey PJ, Ware CB, Mohler KM: TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol 160: 943-952, 1998
48. Panacek E, Marshall J, Fischkoff S, Barchuk W, Teoh L and MONARCS Study Group: Neutralization of TNF by a monoclonal antibody improves survival and reduces organ dysfunction in human sepsis: Results of the MONARCS trial. [Abstract] Chest 118[Suppl 4]: 88S, 2000
49. Cohen J, Carlet J: INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 24: 1431-1440, 1996
50. Mariano F, Guida G, Donati D, Tetta C, Cavalli PL, Verzetti G, Piccoli G, Camussi G: Production of platelet-activating factor in patients with sepsis-associated acute renal failure. Nephrol Dial Transplant 14: 1150-1157, 1999
51. Wang J, Dunn MJ: Platelet-activating factor mediates endotoxin-induced acute renal insufficiency in rats. Am J Physiol 253: F1283-F1289, 1987
52. Tolins JP, Vercellotti GM, Wilkowske M, Ha B, Jacob HS, Raij L: Role of platelet activating factor in endotoxemic acute renal failure in the male rat. J Lab Clin Med 113: 316-324, 1989
53. Healy DP: New and emerging therapies for sepsis. Ann Pharmacother 36: 648-654, 2002
54. Conger J, Robinette J, Villar A, Raij L, Shultz P: Increased nitric oxide synthase activity despite lack of response to endothelium-dependent vasodilators in postischemic acute renal failure in rats. J Clin Invest 96: 631-638, 1995
55. Noiri E, Peresleni T, Miller F, Goligorsky MS: In vivo targeting of inducible NO synthase with oligodeoxynucleotides protects rat kidney against ischemia. J Clin Invest 97: 2377-2383, 1996
56. Morrissey JJ, McCracken R, Kaneto H, Vehaskari M, Montani D, Klahr S: Location of an inducible nitric oxide synthase mRNA in the normal kidney. Kidney Int 45: 998-1005, 1994
57. Landry DW, Oliver JA: The pathogenesis of vasodilatory shock. N Engl J Med 345: 588-595, 2001
58. Yu L, Gengaro PE, Niederberger M, Burke TJ, Schrier RW: Nitric oxide: A mediator in rat tubular hypoxia/reoxygenation injury. Proc Natl Acad Sci USA 91: 1691-1695, 1994
59. Tome LA, Yu L, de Castro I, Campos SB, Seguro AC: Beneficial and harmful effects of L-arginine on renal ischaemia. Nephrol Dial Transplant 14: 1139-1145, 1999
60. Shultz PJ, Raij L: Endogenously synthesized nitric oxide prevents endotoxin-induced glomerular thrombosis. J Clin Invest 90: 1718-1725, 1992
61. Spain DA, Wilson MA, Garrison RN: Nitric oxide synthase inhibition exacerbates sepsis-induced renal hypoperfusion. Surgery 116: 322-330, 1994
62. Booke M, Hinder F, McGuire R, Traber LD, Traber DL: Nitric oxide synthase inhibition versus norepinephrine in ovine sepsis: Effects on regional blood flow. Shock 5: 362-370, 1996
63. Doursout MF, Kilbourn RG, Hartley CJ, Chelly JE: Effects of N-methyl-L-arginine on cardiac and regional blood flow in a dog endotoxin shock model. J Crit Care 15: 22-29, 2000
64. Noiri E, Nakao A, Uchida K, Tsukahara H, Ohno M, Fujita T, Brodsky S, Goligorsky MS: Oxidative and nitrosative stress in acute renal ischemia. Am J Physiol Renal Physiol 281: F948-F957, 2001
65. Rosselet A, Feihl F, Markert M, Gnaegi A, Perret C, Liaudet L: Selective iNOS inhibition is superior to norepinephrine in the treatment of rat endotoxic shock. Am J Respir Crit Care Med 157: 162-170, 1998
66. Cohen RI, Hassell AM, Marzouk K, Marini C, Liu SF, Scharf SM: Renal effects of nitric oxide in endotoxemia. Am J Respir Crit Care Med 164: 1890-1895, 2001
67. Grover R, Zaccardelli D, Colice G, Guntupalli K, Watson D, Vincent JL: An open-label dose escalation study of the nitric oxide synthase inhibitor, N(G)-methyl-L-arginine hydrochloride (546C88), in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. Crit Care Med 27: 913-922, 1999
68. Avontuur JA, Tutein Nolthenius RP, van Bodegom JW, Bruining HA: Prolonged inhibition of nitric oxide synthesis in severe septic shock: A clinical study. Crit Care Med 26: 660-667, 1998
69. Petros A, Lamb G, Leone A, Moncada S, Bennett D, Vallance P: Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res 28: 34-39, 1994
70. Weitzberg E, Lundberg JM, Rudehill A: Elevated plasma levels of endothelin in patients with sepsis syndrome. Circ Shock 33: 222-227, 1991
71. Mitaka C, Hirata Y, Yokoyama K, Nagura T, Tsunoda Y, Amaha K: Improvement of renal dysfunction in dogs with endotoxemia by a nonselective endothelin receptor antagonist. Crit Care Med 27: 146-153, 1999
72. Chin A, Radhakrishnan J, Fornell L, John E: Effects of tezosentan, a dual endothelin receptor antagonist, on the cardiovascular and renal systems of neonatal piglets during endotoxic shock. J Pediatr Surg 37: 482-487, 2002
73. Morise Z, Ueda M, Aiura K, Endo M, Kitajima M: Pathophysiologic role of endothelin-1 in renal function in rats with endotoxin shock. Surgery 115: 199-204, 1994
74. Oldner A, Wanecek M, Goiny M, Weitzberg E, Rudehill A, Alving K, Sollevi A: The endothelin receptor antagonist bosentan restores gut oxygen delivery and reverses intestinal mucosal acidosis in porcine endotoxin shock. Gut 42: 696-702, 1998
75. Gardiner SM, March JE, Kemp PA, Bennett T: Effects of the novel selective endothelin ET(A) receptor antagonist, SB 234551, on the cardiovascular responses to endotoxaemia in conscious rats. Br J Pharmacol 133: 1371-1377, 2001
76. Wang A, Holcslaw T, Bashore TM, Freed MI, Miller D, Rudnick MR, Szerlip H, Thames MD, Davidson CJ, Shusterman N, Schwab SJ: Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. Kidney Int 57: 1675-1680, 2000
77. Klahr S: Role of arachidonic acid metabolites in acute renal failure and sepsis. Nephrol Dial Transplant 9[Suppl 4]: 52-56, 1994
78. Bernard GR, Wheeler AP, Russell JA, Schein R, Summer WR, Steinberg KP, Fulkerson WJ, Wright PE, Christman BW, Dupont WD, Higgins SB, Swindell BB: The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med 336: 912-918, 1997
79. Lugon JR, Boim MA, Ramos OL, Ajzen H, Schor N: Renal function and glomerular hemodynamics in male endotoxemic rats. Kidney Int 36: 570-575, 1989
80. Badr KF, Kelley VE, Rennke HG, Brenner BM: Roles for thromboxane A2 and leukotrienes in endotoxin-induced acute renal failure. Kidney Int 30: 474-480, 1986
81. Cumming AD, McDonald JW, Lindsay RM, Solez K, Linton AL: The protective effect of thromboxane synthetase inhibition on renal function in systemic sepsis. Am J Kidney Dis 13: 114-119, 1989
82. Aiura K, Ueda M, Endo M, Kitajima M: Circulating concentrations and physiologic role of atrial natriuretic peptide during endotoxic shock in the rat. Crit Care Med 23: 1898-1906, 1995
83. Allgren RL, Marbury TC, Rahman SN, Weisberg LS, Fenves AZ, Lafayette RA, Sweet RM, Genter FC, Kurnik BR, Conger JD, Sayegh MH: Anaritide in acute tubular necrosis. Auriculin Anaritide Acute Renal Failure Study Group. N Engl J Med 336: 828-834, 1997
84. Schramm L, Heidbreder E, Lukes M, Weierich T, Lopau K, Zimmermann J, Wanner C: Endotoxin-induced acute renal failure in the rat: Effects of urodilatin and diltiazem on renal function. Clin Nephrol 46: 117-124, 1996
85. Hiki N, Mimura Y: Atrial natriuretic peptide has no potential to protect against endotoxin-induced acute renal failure in the absence of renal nerves. Endocr J 45: 75-81, 1998
86. Sward K, Valson F, Ricksten SE: Long-term infusion of atrial natriuretic peptide (ANP) improves renal blood flow and glomerular filtration rate in clinical acute renal failure. Acta Anaesthesiol Scand 45: 536-542, 2001
87. Rahman SN, Kim GE, Mathew AS, Goldberg CA, Allgren R, Schrier RW, Conger JD: Effects of atrial natriuretic peptide in clinical acute renal failure. Kidney Int 45: 1731-1738, 1994
88. Lewis J, Salem MM, Chertow GM, Weisberg LS, McGrew F, Marbury TC, Allgren RL: Atrial natriuretic factor in oliguric acute renal failure. Anaritide Acute Renal Failure Study Group. Am J Kidney Dis 36: 767-774, 2000
89. Herbert MK, Ginzel S, Muhlschlegel S, Weis KH: Concomitant treatment with urodilatin (ularitide) does not improve renal function in patients with acute renal failure after major abdominal surgery - A randomized controlled trial. Wien Klin Wochenschr 111: 141-147, 1999
90. Meyer M, Pfarr E, Schirmer G, Uberbacher HJ, Schope K, Bohm E, Fluge T, Mentz P, Scigalla P, Forssmann WG: Therapeutic use of the natriuretic peptide ularitide in acute renal failure. Ren Fail 21: 85-100, 1999
91. Kelly KJ, Williams WW Jr, Colvin RB, Meehan SM, Springer TA, Gutierrez-Ramos JC, Bonventre JV: Intercellular adhesion molecule-1-deficient mice are protected against ischemic renal injury. J Clin Invest 97: 1056-1063, 1996
92. Linas SL, Whittenburg D, Repine JE: Role of neutrophil derived oxidants and elastase in lipopolysaccharide-mediated renal injury. Kidney Int 39: 618-623, 1991
93. Linas SL, Whittenburg D, Parsons PE, Repine JE: Mild renal ischemia activates primed neutrophils to cause acute renal failure. Kidney Int 42: 610-616, 1992
94. Kelly KJ, Williams WW Jr, Colvin RB, Bonventre JV: Antibody to intercellular adhesion molecule 1 protects the kidney against ischemic injury. Proc Natl Acad Sci USA 91: 812-816, 1994
95. Haller H, Dragun D, Miethke A, Park JK, Weis A, Lippoldt A, Gross V, Luft FC: Antisense oligonucleotides for ICAM-1 attenuate reperfusion injury and renal failure in the rat. Kidney Int 50: 473-480, 1996
96. Rabb H, Mendiola CC, Dietz J, Saba SR, Issekutz TB, Abanilla F, Bonventre JV, Ramirez G: Role of CD11a and CD11b in ischemic acute renal failure in rats. Am J Physiol 267: F1052-F1058, 1994
97. Lowell CA, Berton G: Resistance to endotoxic shock and reduced neutrophil migration in mice deficient for the Src-family kinases Hck and Fgr. Proc Natl Acad Sci USA 95: 7580-7584, 1998
98. Hayashi H, Imanishi N, Ohnishi M, Tojo SJ: Sialyl Lewis X and anti-P-selectin antibody attenuate lipopolysaccharide-induced acute renal failure in rabbits. Nephron 87: 352-360, 2001
99. Matsukawa A, Lukacs NW, Hogaboam CM, Knibbs RN, Bullard DC, Kunkel SL, Stoolman LM: Mice genetically lacking endothelial selectins are resistant to the lethality in septic peritonitis. Exp Mol Pathol 72: 68-76, 2002
100. Welty-Wolf KE, Carraway MS, Miller DL, Ortel TL, Ezban M, Ghio AJ, Idell S, Piantadosi CA: Coagulation blockade prevents sepsis-induced respiratory and renal failure in baboons. Am J Respir Crit Care Med 164: 1988-1996, 2001
101. Warren HS, Suffredini AF, Eichacker PQ, Munford RS: Risks and benefits of activated protein C treatment for severe sepsis. N Engl J Med 347: 1027-1030, 2002
102. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM; Kyber-Sept Trial Study Group: Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: A randomized controlled trial. JAMA 286: 1869-1878, 2001
103. Eriksson M, Larsson A, Saldeen T, Mattsson C: Melagatran, a low molecular weight thrombin inhibitor, counteracts endotoxin-induced haemodynamic and renal dysfunctions in the pig. Thromb Haemost 80: 1022-1026, 1998
104. Eisele B, Lamy M, Thijs LG, Keinecke HO, Schuster HP, Matthias FR, Fourrier F, Heinrichs H, Delvos U: Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med 24: 663-672, 1998
105. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344: 699-709, 2001
106. Taylor FB Jr, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE: Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 79: 918-925, 1987
107. Humes HD, Cieslinski DA, Coimbra TM, Messana JM, Galvao C: Epidermal growth factor enhances renal tubule cell regeneration and repair and accelerates the recovery of renal function in postischemic acute renal failure. J Clin Invest 84: 1757-1761, 1989
108. Ding H, Kopple JD, Cohen A, Hirschberg R: Recombinant human insulin-like growth factor-I accelerates recovery and reduces catabolism in rats with ischemic acute renal failure. J Clin Invest 91: 2281-2287, 1993
109. Hirschberg R, Ding H: Mechanisms of insulin-like growth factor-I-induced accelerated recovery in experimental ischemic acute renal failure. Miner Electrolyte Metab 24: 211-219, 1998
110. Killion D, Canfield C, Norman J, Rosenthal JT: Exogenous epidermal growth factor fails to accelerate functional recovery in the autotransplanted ischemic pig kidney. J Urol 150: 1551-1556, 1993
111. Hirschberg R, Kopple J, Lipsett P, Benjamin E, Minei J, Albertson T, Munger M, Metzler M, Zaloga G, Murray M, Lowry S, Conger J, McKeown W, O'shea M, Baughman R, Wood K, Haupt M, Kaiser R, Simms H, Warnock D, Summer W, Hintz R, Myers B, Haenftling K, Capra W, et al: Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. Kidney Int 55: 2423-2432, 1999
112. Franklin SC, Moulton M, Sicard GA, Hammerman MR, Miller SB: Insulin-like growth factor I preserves renal function postoperatively. Am J Physiol 272: F257-F259, 1997
113. Takala J, Ruokonen E, Webster NR, Nielsen MS, Zandstra DF, Vundelinckx G, Hinds CJ: Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 341: 785-792, 1999
114. Lieberthal W, Nigam SK: Acute renal failure. II. Experimental models of acute renal failure: Imperfect but indispensable. Am J Physiol Renal Physiol 278: F1-F12, 2000
115. Misset B, Timsit JF, Chevret S, Renaud B, Tamion F, Carlet J: A randomized cross-over comparison of the hemodynamic response to intermittent hemodialysis and continuous hemofiltration in ICU patients with acute renal failure. Intensive Care Med 22: 742-746, 1996
116. John S, Griesbach D, Baumgartel M, Weihprecht H, Schmieder RE, Geiger H: Effects of continuous haemofiltration vs intermittent haemodialysis on systemic haemodynamics and splanchnic regional perfusion in septic shock patients: A prospective, randomized clinical trial. Nephrol Dial Transplant 16: 320-327, 2001
117. Yagi N, Leblanc M, Sakai K, Wright EJ, Paganini EP: Cooling effect of continuous renal replacement therapy in critically ill patients. Am J Kidney Dis 32: 1023-1030, 1998
118. Schortgen F, Soubrier N, Delclaux C, Thuong M, Girou E, Brun-Buisson C, Lemaire F, Brochard L: Hemodynamic tolerance of intermittent hemodialysis in critically ill patients: Usefulness of practice guidelines. Am J Respir Crit Care Med 162: 197-202, 2000
119. Kellum JA, Angus DC, Johnson JP, Leblanc M, Griffin M, Ramakrishnan N, Linde-Zwirble WT: Continuous versus intermittent renal replacement therapy: A meta-analysis. Intensive Care Med 28: 29-37, 2002
120. Swartz RD, Messana JM, Orzol S, Port FK: Comparing continuous hemofiltration with hemodialysis in patients with severe acute renal failure. Am J Kidney Dis 34: 424-432, 1999
121. Guerin C, Girard R, Selli JM, Ayzac L: Intermittent versus continuous renal replacement therapy for acute renal failure in intensive care units: Results from a multicenter prospective epidemiological survey. Intensive Care Med 28: 1411-1418, 2002
122. Mehta RL, McDonald B, Gabbai FB, Pahl M, Pascual MT, Farkas A, Kaplan RM; Collaborative Group for Treatment of ARF in the ICU: A randomized clinical trial of continuous versus intermittent dialysis for acute renal failure. Kidney Int 60: 1154-1163, 2001
123. Sandy D, Moreno L, Lee JC, Paganini EP: A randomised, stratified, dose equivalent comparison of continuous veno-venous hemodialysis versus intermittent hemodialysis support in ICU acute renal failure [Abstract]. J Am Soc Nephrol 9: 225A, 1998
124. Oudemans-van Straaten HM, Bosman RJ, van der Spoel JI, Zandstra DF: Outcome of critically ill patients treated with intermittent high-volume haemofiltration: A prospective cohort analysis. Intensive Care Med 25: 814-821, 1999
125. Ronco C, Bellomo R, Homel P, Brendolan A, Dan M, Piccinni P, La Greca G: Effects of different doses in continuous venovenous haemofiltration on outcomes of acute renal failure: A prospective randomised trial. Lancet 356: 26-30, 2000
126. Bouman CS, Oudemans-Van Straaten HM, Tijssen JG, Zandstra DF, Kesecioglu J: Effects of early high-volume continuous venovenous hemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: A prospective, randomized trial. Crit Care Med 30: 2205-2211, 2002
127. Kumar VA, Craig M, Depner TA, Yeun JY: Extended daily dialysis: A new approach to renal replacement for acute renal failure in the intensive care unit. Am J Kidney Dis 36: 294-300, 2000
128. Marshall MR, Golper TA, Shaver MJ, Alam MG, Chatoth DK: Sustained low-efficiency dialysis for critically ill patients requiring renal replacement therapy. Kidney Int 60: 777-785, 2001
129. Marshall MR, Golper TA, Shaver MJ, Alam MG, Chatoth DK: Urea kinetics during sustained low-efficiency dialysis in critically ill patients requiring renal replacement therapy. Am J Kidney Dis 39: 556-570, 2002
130. De Vriese AS, Vanholder R, Pascual M, Lameire N, Colardyn F: Can inflammatory mediators be removed efficiently by continuous renal replacement techniques? Intensive Care Med 25: 903-910, 1999
131. De Vriese AS, Colardyn F, Lameire N: Continuous renal replacement therapies in sepsis: Do they matter? In: Yearbook of Intensive Care and Emergency Medicine, edited by Vincent JL, 1999, pp 611-620
132. De Vriese AS, Colardyn F, Philippé J, Vanholder R, De Sutter J, Lameire N: Cytokine removal during continuous hemofiltration in septic patients. J Am Soc Nephrol 10: 846-853, 1999
133. Sieberth HG, Kierdorf HP: Is cytokine removal by continuous hemofiltration feasible? Kidney Int Suppl 72: S79-S83, 1999
134. Tetta C, Gianotti L, Cavaillon JM, Wratten ML, Fini M, Braga M, Bisagni P, Giavaresi G, Bolzani R, Giardino R: Coupled plasma filtration-adsorption in a rabbit model of endotoxic shock. Crit Care Med 28: 1526-1533, 2000
135. Ronco C, Brendolan A, Lonnemann G, Bellomo R, Piccinni P, Digito A, Dan M, Irone M, La Greca G, Inguaggiato P, Maggiore U, De Nitti C, Wratten ML, Ricci Z, Tetta C: A pilot study of coupled plasma filtration with adsorption in septic shock. Crit Care Med 30: 1250-1255, 2002
136. Cole L, Bellomo R, Journois D, Davenport P, Baldwin I, Tipping P: High-volume haemofiltration in human septic shock. Intensive Care Med 27: 978-986, 2001
137. Cole L, Bellomo R, Hart G, Journois D, Davenport P, Tipping P, Ronco C: A phase II randomized, controlled trial of continuous hemofiltration in sepsis. Crit Care Med 30: 100-106, 2002
138. Uchino S, Bellomo R, Goldsmith D, Davenport P, Cole L, Baldwin I, Panagiotopoulos S, Tipping P: Super high flux hemofiltration: A new technique for cytokine removal. Intensive Care Med 28: 651-655, 2002